Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BIO logo BIO
Upturn stock ratingUpturn stock rating
BIO logo

Bio-Rad Laboratories Inc (BIO)

Upturn stock ratingUpturn stock rating
$251.56
Last Close (24-hour delay)
Profit since last BUY0.36%
upturn advisory
Consider higher Upturn Star rating
BUY since 2 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/03/2025: BIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $315.33

1 Year Target Price $315.33

Analysts Price Target For last 52 week
$315.33 Target price
52w Low $211.43
Current$251.56
52w High $387.99

Analysis of Past Performance

Type Stock
Historic Profit -19.09%
Avg. Invested days 40
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/03/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 6.76B USD
Price to earnings Ratio -
1Y Target Price 315.33
Price to earnings Ratio -
1Y Target Price 315.33
Volume (30-day avg) 6
Beta 0.94
52 Weeks Range 211.43 - 387.99
Updated Date 07/3/2025
52 Weeks Range 211.43 - 387.99
Updated Date 07/3/2025
Dividends yield (FY) -
Basic EPS (TTM) -76.52

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -85.16%
Operating Margin (TTM) 9.72%

Management Effectiveness

Return on Assets (TTM) 1.55%
Return on Equity (TTM) -27.52%

Valuation

Trailing PE -
Forward PE 32.26
Enterprise Value 6447599905
Price to Sales(TTM) 2.66
Enterprise Value 6447599905
Price to Sales(TTM) 2.66
Enterprise Value to Revenue 2.54
Enterprise Value to EBITDA -13.07
Shares Outstanding 22142400
Shares Floating 18657507
Shares Outstanding 22142400
Shares Floating 18657507
Percent Insiders 16.14
Percent Institutions 93.04

ai summary icon Upturn AI SWOT

Bio-Rad Laboratories Inc

stock logo

Company Overview

overview logo History and Background

Bio-Rad Laboratories, Inc. was founded in 1952 in Berkeley, California. Initially focused on biochemical research supplies, it expanded into clinical diagnostics and life science research products, becoming a major player in these fields.

business area logo Core Business Areas

  • Life Science: Develops, manufactures, and markets a wide range of reagents, instruments, and software used in biological and medical research. This includes products for genomics, proteomics, cell biology, and bioprocessing.
  • Clinical Diagnostics: Offers a comprehensive line of in vitro diagnostics products for clinical laboratories, including quality controls, instruments, and reagents for immunoassay, clinical chemistry, and molecular diagnostics.

leadership logo Leadership and Structure

Norman Schwartz is the Chairman and CEO. The company operates with a functional organizational structure, encompassing various departments such as R&D, manufacturing, marketing, sales, and finance.

Top Products and Market Share

overview logo Key Offerings

  • Droplet Digital PCR (ddPCR): ddPCR is a highly precise method for quantifying nucleic acids. Competitors include Thermo Fisher Scientific (QX200 ddPCR System) and QIAGEN (QIAcuity Digital PCR System). Market share of ddPCR can vary regionally but Bio-Rad is a major player. Market analysis and reports estimate Bio-Rad's ddPCR system accounts for about 30-40% market share.
  • Antibodies and Reagents: Bio-Rad offers a wide range of antibodies and reagents for various research applications. Key Competitors include Thermo Fisher Scientific, Cell Signaling Technology, Abcam and Merck KGaA. These are crucial to the life science research market. Market share estimates place Bio-Rad in the top 5 antibody suppliers worldwide, estimated at 5-10%.
  • Quality Controls: Bio-Rad offers quality controls for use in clinical diagnostics labs. Competitors include Roche, Abbott, and Siemens Healthineers. It is estimated that Bio-Rad accounts for 10-15% of the quality control market.

Market Dynamics

industry overview logo Industry Overview

The life science and clinical diagnostics industries are experiencing strong growth due to advancements in genomics, personalized medicine, and increasing demand for diagnostic testing. These industries are highly regulated and competitive.

Positioning

Bio-Rad is a well-established player in both the life science and clinical diagnostics markets. Its competitive advantages include a broad product portfolio, strong brand reputation, and global distribution network.

Total Addressable Market (TAM)

The TAM for Bio-Rad's markets (Life Science & Clinical Diagnostics) is estimated at hundreds of billions USD. Bio-Rad has a solid position and is well poised to capture TAM value.

Upturn SWOT Analysis

Strengths

  • Strong brand reputation
  • Diverse product portfolio
  • Global distribution network
  • High investment in R&D

Weaknesses

  • Dependence on key products
  • Exposure to regulatory changes
  • Slower growth in certain product segments

Opportunities

  • Expanding into emerging markets
  • Developing new diagnostic technologies
  • Acquiring complementary businesses
  • Partnering with pharmaceutical companies

Threats

  • Intense competition
  • Price pressures
  • Technological obsolescence
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • Thermo Fisher Scientific (TMO)
  • Danaher Corporation (DHR)
  • Agilent Technologies (A)
  • Roche Holding AG (RO.SW)

Competitive Landscape

Bio-Rad competes with larger and smaller companies in various segments. Its strengths lie in specific technologies and customer relationships, while larger competitors benefit from scale and broader product portfolios.

Major Acquisitions

S1000 touch Thermal Cycler

  • Year: 2012
  • Acquisition Price (USD millions):
  • Strategic Rationale: Added to PCR product lines

Growth Trajectory and Initiatives

Historical Growth: Bio-Rad has experienced steady growth driven by product innovation and strategic acquisitions.

Future Projections: Analyst projections vary, but generally anticipate continued growth in line with industry trends.

Recent Initiatives: Recent initiatives include new product launches, acquisitions, and partnerships to expand market reach.

Summary

Bio-Rad is a strong player in the life science and clinical diagnostics markets, with a diverse product portfolio and global reach. Its focus on innovation and strategic acquisitions is fueling growth. Competitive pressures and economic uncertainties are factors to watch out for. Continued investments in R&D and expansion into emerging markets should help.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Financial Reports
  • Industry Analysis Reports
  • Company Press Releases
  • Third party equity research reports
  • Market data platforms

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bio-Rad Laboratories Inc

Exchange NYSE
Headquaters Hercules, CA, United States
IPO Launch date 1966-01-01
Chairman & CEO Mr. Norman D. Schwartz
Sector Healthcare
Industry Medical Devices
Full time employees 7700
Full time employees 7700

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.